BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30443411)

  • 1. Evaluation of intraductal delivery of poly(ethylene glycol)-doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)-like lesions in rats.
    Gu Z; Al-Zubaydi F; Adler D; Li S; Johnson S; Prasad P; Holloway J; Szekely Z; Love S; Gao D; Sinko PJ
    J Interdiscip Nanomed; 2018 Sep; 3(3):146-159. PubMed ID: 30443411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of size and polymer architecture of doxorubicin-poly(ethylene) glycol conjugate nanocarriers on breast duct retention, potency and toxicity.
    Gu Z; Gao D; Al-Zubaydi F; Li S; Singh Y; Rivera K; Holloway J; Szekely Z; Love S; Sinko PJ
    Eur J Pharm Sci; 2018 Aug; 121():118-125. PubMed ID: 29698706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy.
    Al-Zubaydi F; Gao D; Kakkar D; Li S; Adler D; Holloway J; Szekely Z; Gu Z; Chan N; Kumar S; Love S; Sinko PJ
    J Control Release; 2020 Jul; 323():71-82. PubMed ID: 32302762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-functional nanocarriers based on iron oxide nanoparticles conjugated with doxorubicin, poly(ethylene glycol) and folic acid as theranostics for cancer therapy.
    Rajkumar S; Prabaharan M
    Colloids Surf B Biointerfaces; 2018 Oct; 170():529-537. PubMed ID: 29966906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraductal delivery of nanocarriers for ductal carcinoma
    Pandey M; Wen PX; Ning GM; Xing GJ; Wei LM; Kumar D; Mayuren J; Candasamy M; Gorain B; Jain N; Gupta G; Dua K
    Nanomedicine (Lond); 2022 Oct; 17(24):1871-1889. PubMed ID: 36695306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Legumain-cleavable 4-arm poly(ethylene glycol)-doxorubicin conjugate for tumor specific delivery and release.
    Zhou H; Sun H; Lv S; Zhang D; Zhang X; Tang Z; Chen X
    Acta Biomater; 2017 May; 54():227-238. PubMed ID: 28315495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Anticancer Efficacy and Toxicity Studies of a Novel Polymer Conjugate N-Acetyl Glucosamine (NAG)-PEG-Doxorubicin for Targeted Cancer Therapy.
    Pawar S; Mahajan K; Vavia P
    AAPS PharmSciTech; 2017 Nov; 18(8):3021-3033. PubMed ID: 28497240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The enhanced chemotherapeutic effects of doxorubicin loaded PEG coated TiO
    Du Y; Ren W; Li Y; Zhang Q; Zeng L; Chi C; Wu A; Tian J
    J Mater Chem B; 2015 Feb; 3(8):1518-1528. PubMed ID: 32262424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery.
    Prabaharan M; Grailer JJ; Pilla S; Steeber DA; Gong S
    Biomaterials; 2009 Oct; 30(30):6065-75. PubMed ID: 19674777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn H40, poly(L-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery.
    Prabaharan M; Grailer JJ; Pilla S; Steeber DA; Gong S
    Biomaterials; 2009 Jun; 30(16):3009-19. PubMed ID: 19250665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of molecular size on the retention of polymeric nanocarrier diagnostic agents in breast ducts.
    Singh Y; Gao D; Gu Z; Li S; Rivera KA; Stein S; Love S; Sinko PJ
    Pharm Res; 2012 Sep; 29(9):2377-88. PubMed ID: 22569800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio.
    Baabur-Cohen H; Vossen LI; Krüger HR; Eldar-Boock A; Yeini E; Landa-Rouben N; Tiram G; Wedepohl S; Markovsky E; Leor J; Calderón M; Satchi-Fainaro R
    J Control Release; 2017 Jul; 257():118-131. PubMed ID: 27374630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ethylene glycol)-doxorubicin conjugates containing beta-lactamase-sensitive linkers.
    Senter PD; Svensson HP; Schreiber GJ; Rodriguez JL; Vrudhula VM
    Bioconjug Chem; 1995; 6(4):389-94. PubMed ID: 7578358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery.
    Prabaharan M; Grailer JJ; Pilla S; Steeber DA; Gong S
    Biomaterials; 2009 Oct; 30(29):5757-66. PubMed ID: 19643472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
    Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z
    Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive detection of passively targeted poly(ethylene glycol) nanocarriers in tumors.
    Singh Y; Gao D; Gu Z; Li S; Stein S; Sinko PJ
    Mol Pharm; 2012 Jan; 9(1):144-55. PubMed ID: 22077582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Insights into the Loading and Dynamics of Doxorubicin on PEGylated Graphene Oxide Nanocarriers.
    Mahdavi M; Fattahi A; Tajkhorshid E; Nouranian S
    ACS Appl Bio Mater; 2020 Mar; 3(3):1354-1363. PubMed ID: 33313482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
    Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
    Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy.
    Al-Zubaydi F; Gao D; Kakkar D; Li S; Holloway J; Szekely Z; Chan N; Kumar S; Sabaawy HE; Love S; Sinko PJ
    Drug Deliv Transl Res; 2022 Jan; 12(1):240-256. PubMed ID: 33590464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.